Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3699-3706

  Elting, Linda S ^a   Rubenstein, Edward B ^a   Rolston, Kenneth ^a   Cantor, Scott B ^a   Martin, Charles G ^a   Kurtin, Danna ^a   Rodriguez, Saul ^a   Lam, Tony ^a   Kanesan, Krishnakumari ^a   Bodey, Gerald ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CORTICOSTEROID; IMIPENEM; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034331492     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3699     Document Type: Article

References (26)

1. Antibiotics in patients with neutropenia
2. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia
3. Overview of empiric antibiotic therapy for the febrile neutropenic patient
4. Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges
5. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
6. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
7. The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation
8. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
9. Outpatient treatment of febrile episodes in neutropenic cancer patients: A randomized prospective comparison of oral ciprofloxacin and clindamycin to intravenous aztreonam and clindamycin
10. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms
11. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients
12. Imipenem/cilastatin therapy of infections in cancer patients
13. Beta-lactam regimens in febrile neutropenic cancer patients
14. Beta-lactam regimens for the febrile neutropenic patient
15. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients
16. Outcomes of bacteremia in neutropenic cancer patients: Observations from two decades of epidemiologic and clinical trials
17. Economic evaluation of management strategies for low-risk febrile neutropenic cancer patients
18. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
19. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient
20. Management of fever of unknown origin in patients with neoplasms and neutropenia
21. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer
22. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient
23. Duration of intravenous antibiotics for patients with neutropenic fever
24. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
25. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
26. Fever and neutropenia: How to use a new treatment strategy